When do we dare to stop biological or immunomodulatory therapy for Crohn's disease? Results of a multidisciplinary European expert panel

Journal of Crohn's and Colitis

Volumn 7, Issue 10, 2013, Pages 820-826

  Pittet, Valerie ^a   Froehlich, Florian ^b,c   Maillard, Michel H ^b   Mottet, Christian ^a,b,d   Gonvers, Jean Jacques ^b   Felley, Christian ^e   Vader, John Paul ^a   Burnand, Bernard ^a   Michetti, Pierre ^b,e   Schoepfer, Alain ^b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d Service of Gastroenterology HÔpital Neuchâtelois   (Switzerland)

^e Crohn and Colitis Center   (Switzerland)

Author keywords

Anti TNF drugs; Azathioprine; Crohn's disease; Treatment cessation; Treatment stopping rules

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; CALGRANULIN; CERTOLIZUMAB PEGOL; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE;

COLONOSCOPY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE ACTIVITY; GASTROENTEROLOGIST; HUMAN; IMMUNOMODULATION; MAINTENANCE THERAPY; MEDICAL EXPERT; MONOTHERAPY; PRIORITY JOURNAL; REMISSION; REVIEW; TREATMENT WITHDRAWAL;

ANTI-TNF DRUGS; AZATHIOPRINE; CROHN'S DISEASE; TREATMENT CESSATION; TREATMENT STOPPING RULES;

C-REACTIVE PROTEIN; COLONOSCOPY; CROHN DISEASE; FECES; HUMANS; IMMUNOMODULATION; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTE L1 ANTIGEN COMPLEX; REMISSION INDUCTION; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; WITHHOLDING TREATMENT;

EID: 84884138341     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2013.04.013     Document Type: Review

References (37)

1. Prefontaine E., Sutherland L.R., Macdonald J.K., Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009, CD000067.
2. Hindorf U., Johansson M., Eriksson A., Kvifors E., Almer S.H. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther 2009, 29:654-661.
3. Feagan B.G., Fedorak R.N., Irvine E.J., Wild G., Sutherland L., Steinhart A.H., et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000, 342:1627-1632.
4. Colombel J.F., Sandborn W.J., Reinisch W., Mantzaris G.J., Kornbluth A., Rachmilewitz D., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362:1383-1395.
5. Colombel J.F., Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Panaccione R., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
6. Colombel J.F., Sandborn W.J., Rutgeerts P., Kamm M.A., Yu A.P., Wu E.Q., et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am J Gastroenterol 2009, 104:1170-1179.
7. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
8. Schnitzler F., Fidder H., Ferrante M., Noman M., Arijs I., Van Assche G., et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009, 58:492-500.
9. Schreiber S., Colombel J.F., Bloomfield R., Nikolaus S., Scholmerich J., Panes J., et al. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol 2010, 105:1574-1582.
10. Schreiber S., Khaliq-Kareemi M., Lawrance I.C., Thomsen O.O., Hanauer S.B., McColm J., et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007, 357:239-250.
11. Sokol H., Seksik P., Carrat F., Nion-Larmurier I., Vienne A., Beaugerie L., et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010, 59:1363-1368.
12. Lemann M., Mary J-Y., Colombel J-F., Duclos B., Soule J-C., Lerebours E., et al. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 2005, 128:1812-1818.
13. Treton X., Bouhnik Y., Mary J.Y., Colombel J.F., Duclos B., Soule J.C., et al. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol 2009, 7:80-85.
14. Louis E., Mary J-Y., Vernier-Massouille G., Grimaud J-C., Bouhnik Y., Laharie D., et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012, 142:63-70.
15. Beaugerie L., Brousse N., Bouvier A.M., Colombel J.F., Lemann M., Cosnes J., et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009, 374:1617-1625.
16. D'Haens G., Rutgeerts P. Immunosuppression-associated lymphoma in IBD. Lancet 2009, 374:1572-1573.
17. Siegel C.A., Marden S.M., Persing S.M., Larson R.J., Sands B.E. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009, 7:874-881.
18. Biancone L., Petruzziello C., Orlando A., Kohn A., Ardizzone S., Daperno M., et al. Cancer in Crohn's disease patients treated with infliximab: a long-term multicenter matched pair study. Inflamm Bowel Dis 2011, 17:758-766.
19. Lichtenstein G.R., Feagan B.G., Cohen R.D., Salzberg B.A., Diamond R.H., Chen D.M., et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006, 4:621-630.
20. Felley C., Vader J.P., Juillerat P., Pittet V., O'Morain C., Panis Y., et al. Appropriate therapy for fistulizing and fibrostenotic Crohn's disease: results of a multidisciplinary expert panel - EPACT II. J Crohns Colitis 2009, 3:250-256.
21. Juillerat P., Vader J.P., Felley C., Pittet V., Gonvers J.J., Mottet C., et al. Appropriate maintenance treatment for Crohn's disease: results of a multidisciplinary international expert panel - EPACT II. J Crohns Colitis 2009, 3:241-249.
22. Michetti P., Stelle M., Juillerat P., Gassull M., Heil F.J., Stange E., et al. Appropriateness of therapy for active Crohn's disease: results of a multidisciplinary international expert panel-EPACT II. J Crohns Colitis 2009, 3:232-240.
23. Mottet C., Vader J.P., Felley C., Froehlich F., Gonvers J.J., Juillerat P., et al. Appropriate management of special situations in Crohn's disease (upper gastro-intestinal; extra-intestinal manifestations; drug safety during pregnancy and breastfeeding): results of a multidisciplinary international expert panel-EPACT II. J Crohns Colitis 2009, 3:257-263.
24. Brook R.H., Chassin M.R., Fink A., Solomon D.H., Kosecoff J., Park R.E. A method for the detailed assessment of the appropriateness of medical technologies. Int J Technol Assess Health Care 1986, 2:53-63.
25. Naylor C.D. What is appropriate care?. N Engl J Med 1998, 338:1918-1920.
26. Fitch K. The Rand/UCLA appropriateness method user's manual 2001, Rand, Santa Monica.
27. Panes J., Bouzas R., Chaparro M., Garcia-Sanchez V., Gisbert J.P., Martinez de Guerenu B., et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease. Aliment Pharmacol Ther 2011, 34:125-145.
28. Schoepfer A.M., Beglinger C., Straumann A., Trummler M., Vavricka S.R., Bruegger L.E., et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010, 105:162-169.
29. French H., Mark Dalzell A., Srinivasan R., El-Matary W. Relapse rate following azathioprine withdrawal in maintaining remission for Crohn's disease: a meta-analysis. Dig Dis Sci 2011, 56:1929-1936.
30. Waugh A.W.G., Garg S., Matic K., Gramlich L., Wong C., Sadowski D.C., et al. Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort. Aliment Pharmacol Ther 2010, 32:1129-1134.
31. Sandborn W.J. The future of inflammatory bowel disease therapy: where do we go from here?. Dig Dis 2012, 30(Suppl. 3):140-144.
32. Colombel J.F., Louis E., Peyrin-Biroulet L., Sandborn W.J., Panaccione R. Deep remission: a new concept?. Dig Dis 2012, 30(Suppl. 3):107-111.
33. Baert F., Moortgat L., Van Assche G., Caenepeel P., Vergauwe P., De Vos M., et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010, 138:463-468. [quiz e410-461].
34. Molander P., Sipponen T., Kemppainen H., Jussila A., Blomster T., Koskela R., et al. Achievement of deep remission during scheduled maintenance therapy with TNFalpha-blocking agents in IBD. J Crohns Colitis 2013, 10.1016/j.crohns.2012.10.018.
35. Savoye G., Savoye-Collet C. How deep is remission in perianal Crohn's disease and do imaging modalities matter?. Am J Gastroenterol 2010, 105:1445-1446. [author reply 1446].
36. Zallot C., Peyrin-Biroulet L. Deep remission in inflammatory bowel disease: looking beyond symptoms. Curr Gastroenterol Rep 2013, 15:315.
37. Travis S., Feagan B.G., Rutgeerts P., van Deventer S. The future of inflammatory bowel disease management: combining progress in trial design with advances in targeted therapy. J Crohns Colitis 2012, 6(Suppl. 2):S250-S259.